Table 1.
Demographics and Clinical/Laboratory Characterization of Study Subjects by Postvaccination Responses.
| Number of Patients(% of total patient number) | Group A: Adequate baseline-pPA | Group B: Adequate post-pPA | Group C: Inadequate post-pPA (SAD) | Total P Value | P Value: Group A vs Group B | P Value: Group A vs Group C | P Value: Group B vs Group C | |
|---|---|---|---|---|---|---|---|---|
| Patient cohort (%) | 313 | 58 (19) | 193 (62) | 62 (20) | ||||
| Median age | 34 | 31 | 35 | 41 | .02 | .54 | .06 | .006 |
| Ethnicity (white /other) | 268/45 | 51/7 | 163/30 | 54/8 | .75 | .51 | .89 | .62 |
| Male/female | 111/202 | 15/43 | 73/120 | 23/39 | .24 | .09 | .18 | .91 |
| Recurrent infection (%) | 241 (77) | 43 (74) | 146 (76) | 52 (84) | .35 | .81 | .19 | .18 |
| No infection (%) | 72 (23) | 15 (26) | 47 (24) | 10 (14) | .35 | .81 | .19 | .18 |
| Chronic rhinosinusitis (%) | 143(45) | 15 (26) | 91 (47) | 37 (60) | .0008 | .04 | .0002 | .08 |
| Recurrent acute sinusitis (%) | 61 (24) | 12 (21) | 38 (20) | 11 (18) | .91 | .87 | .68 | .74 |
| Recurrent upper respiratory infection (%) | 37(12) | 16 (27) | 17 (9) | 4 (6) | .03 | .0002 | .002 | .56 |
| Allergy sensitization (%) | 194 (62) | 29 (50) | 128 (66) | 37 (60) | .07 | .02 | .29 | .34 |
| Asthma (%) | 134 (43) | 25 (43) | 81 (42) | 28 (45) | .90 | .88 | .82 | .66 |
| Allergic asthma (%) | 100 (32) | 13 (22) | 66 (34) | 21 (34) | .23 | .09 | .16 | .96 |
| Rhinitis (allergic and nonallergic) (%) | 242 (77) | 43 (74) | 153 (79) | 46 (74) | .58 | .41 | .99 | .4 |
| Allergic rhinitis (%) | 177 (57) | 26 (45) | 120 (62) | 31 (50) | .03 | .019 | .5 | .08 |
Abbreviations: pPA, percentage of protective (≥1.3 µg/mL) pneumococcal antibody serotypes/total tested serotypes; SAD, specific antibody deficiency.
Bold values indicate statistical significance (P < .05). Baseline-pPA denotes prevaccination pPA and post-pPA denotes postvaccination pPA.